Table 2.

Comparison of PANSS, ITAQ, DAI and TESS scores between patients on olanzapine and other SGAs ¹ with analysis of variance of repeated measures

Variables	Admission		Discharge		Time effect		Group effect		Time×Group
	Olanzapine (n=62)	Other SGAs1 (n=86)	Olanzapine (n=62)	Other SGAs1 (n=86)	F	p	F	p	F	p
PANSS positive	24.4(6.5)	22.5(6.3)	11.8(4.0)	11.9(3.9)	26.13	<0.001	0.06	0.804	3.55	0.061
PANSS negative	23.5(8.1)	24.9(8.8)	18.0(7.0)	19.5(7.8)	106.16	<0.001	1.53	0.218	0.01	0.967
PANSS general (no insight item)	38.2(7.7)	38.8(8.7)	26.0(6.5)	27.5(7.5)	363.73	<0.001	0.85	0.358	0.60	0.439
G12 (insight item)	5.4(1.2)	5.4(1.2)	3.2(1.0)	4.0(1.2)	220.65	<0.001	9.11	0.003	8.68	0.004
ITAQ 1	2.0(2.2)	1.7(1.9)	6.2(3.0)	4.8(3.1)	278.83	<0.001	5.99	0.016	6.56	0.011
ITAQ 2	3.1(3.2)	3.1(2.9)	7.5(3.2)	6.1(3.2)	180.90	<0.001	2.53	0.113	6.70	0.011
DAI	0.6(5.0)	2.0(4.9)	4.6(3.6)	4.3(4.0)	46.00	<0.001	0.81	0.370	3.75	0.055
TESS
Toxic symptom	0.37(0.70)	0.18(0.59)	1.23(1.14)	0.90(1.02)	65.88	<0.001	1.44	0.232	0.49	0.485
Abnormal test	0.20(0.31)	0.33(0.64)	0.63(0.97)	0.41(0.81)	8.54	0.004	0.28	0.601	4.23	0.041
Nervous system	0.30(0.84)	0.60(1.14)	0.46(0.89)	0.34(0.73)	0.26	0.613	0.55	0.461	4.67	0.032
Vegetative nervous system	0.46(0.86)	0.34(0.67)	0.32(0.73)	0.23(0.66)	2.72	0.101	1.30	0.255	0.05	0.816
Cardiovascular	0.10(0.25)	0.17(0.62)	0.30(0.63)	0.24(0.74)	3.52	0.063	0.74	0.392	0.74	0.382
Others†	0.46(0.62)	0.34(0.46)	0.30(1.08)	0.60(0.84)	25.49	<0.001	4.49	0.036	3.95	0.049

¹See Table 1

Abbreviations: PANSS: Positive and Negative Syndrome Scale; ITAQ: Insight and Treatment Attitudes Questionnaire; DAI: Drug Attitude Inventory; TESS: Treatment Emergent Symptoms Scale.

†, include 6 items (skin allergy, weight gain, weight reduction, anorexia, headache and tardive dyskinesia).

SGAs=second-generation antipsychotics